The Future of Psilocybin
in Alzheimer
Disease Treatment
About Us
Ixtlan Bioscience is an Israeli based biotech company devoted to defining and utilizing psilocybin microdosing in order to find a new and better class of mental health therapies for brain pathologies. Our mission is to advance safe and accessible psychedelic medicine to slow down the progression of Alzheimer’s and dementia diseases.
Dementia in numbers
46.8m
2015
2030
74.7m
131.5m
2050
Ixtlan AD Kit
Ixtlan AD Kit comprises a unique kit for the treatment of a variety of brain pathologies by micro-dosing of encapsulated 5HT2A receptor agonists, specifically psilocybin, along with
Encapsulated psilocybin micro-doses.
An explicit use-protocol, carefully tailored under medical supervision, making it easy and safe for
in-home administration;
A physical product in a form of games and exercises, that will be tailored for different levels of cognitive impairment;
A propriety web application dedicated for providing personalized and tailored cognitive exercise by psilocybin microdoses, as well as monitoring the patient;
A uniqne home test for detection of psilocybin metabolites concentrations – with purpose of providing data on the individual differences in psilocybin metabolism vs it’s effects/therapeutical power.
The Science
The renaissance in hallucinogenic mushrooms derived psilocybin research in recent years, coupled with anecdotal reports of cognitive benefits from microdosing, suggests that they may have a therapeutic role in a range of psychiatric and neurological conditions. At Ixtlan Bioscience, we attempt to secure pioneering position in this exciting, promising field of novel therapeutic approach for brain pathologies, by partnering with eminent scientific institutions and conducting extensive pre-clinical and clinical.
Psilocybin microdosing is the practice of using sub-threshold doses (microdoses) of serotonergic drugs in an attempt to promote emotional balance, increase performance on problems-solving tasks and to treat anxiety and depression.
According to currently available data from preclinical and clinical trials, and advantage of microdosing is reflected in it’s safety, as microdosing therapeutical psychedelics does not cause side effects, changes in perception and impaired functioning.
Microdosing
Micro-dosing psilocybin is a safe and preferable protocol of administrating therapeutic psychedelics as it does not cause changes in perception and does not impair mental or physical performance. Micro-dosing psilocybin has shown a 20% increase in neuronal branching in mice, allowing development of new connections in the brain. Psilocybin micro-dosing is the practice of using sub-threshold doses (micro-doses) of serotonergic drugs in an attempt to promote emotional balance, increase performance on problems-solving tasks and to treat anxiety and depression.
Dementia
As human life expectancy increases at an ever-faster rate, the probability of being affected by dementia rises. Currently there are no satisfying treatments for Alzheimer’s disease and other dementias. Available treatment options are insufficient and expensive and therefore not available for a major part of the population worldwide.
The healthcare system today has a huge lack of an in-home neurorecovery solutions, which would provide accessibility to those unable to easily commute to receive therapy in person. Global Unmet Need for Psychedelic Based Treatments in Dementia Globally an estimated 50 million people have a diagnosis of dementia and population prevalence continues to increase.
